Author/Authors :
Shouda، نويسنده , , Takanori and Hiraoka، نويسنده , , Koji and Komiya، نويسنده , , Setsuro and Hamada، نويسنده , , Tetsuya and Zenmyo، نويسنده , , Michihisa and Iwasaki، نويسنده , , Hiroshi and Isayama، نويسنده , , Teruto and Fukushima، نويسنده , , Nobuhiro and Nagata، نويسنده , , Kensei and Yoshimura، نويسنده , , Akihiko، نويسنده ,
Abstract :
There is no established optimum treatment for malignant fibrous histiocytoma (MFH) at present, and few MFH cell lines are established. In the present study, we established new MFH cell lines, KHZ-MFH and SFT85-03, and investigated the JAK/STAT (Janus kinase/signal transducer and activator of transcription) signaling pathway. We found that MFH cells secreted high levels of IL-6 and that STAT3 was constitutively activated in these cells. The JAK2 kinase inhibitor, tyrphostin AG490, suppressed the growth of MFH cells and inhibited the secretion of IL-6. Furthermore, blockade of activated STAT3 by forced expression of a cytokine signaling repressor, SOCS3 gene as well as a dominant-negative STAT3 in these cells significantly suppressed their growth. These results indicated that an autocrine mechanism of the JAK/STAT3 signaling pathway could promote the growth of MFH cells and that this pathway could be a therapeutic target of MFH.
